Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

Similar articles for PubMed (Select 16112244)

1.

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.

Sengul AM, Altuntas Y, Kürklü A, Aydin L.

Diabetes Res Clin Pract. 2006 Feb;71(2):210-9. Epub 2005 Aug 19.

PMID:
16112244
2.

Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria.

Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P.

Eur J Clin Pharmacol. 2005 Aug;61(7):483-90. Epub 2005 Jul 15.

PMID:
16021438
3.

Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.

Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE.

Am J Hypertens. 2008 Feb;21(2):172-6. doi: 10.1038/ajh.2007.2. Epub 2008 Jan 10.

PMID:
18188164
4.

Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats.

Wienen W, Richard S, Champeroux P, Audeval-Gerard C.

J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1):31-6.

PMID:
11881063
5.

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi: 10.1093/ndt/gfn230. Epub 2008 May 1.

7.

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.

Rippin J, Bain SC, Barnett AH; DETAIL study.

J Diabetes Complications. 2002 May-Jun;16(3):195-200.

PMID:
12015188
8.

A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.

Kulkarni RB, Kulkarni BN, Hariharan RS, Naikwadi A, Gawde A, Baliga V, Desai A.

J Indian Med Assoc. 2005 Mar;103(3):187-91.

PMID:
16173297
9.

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.

Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P.

J Hum Hypertens. 2006 Mar;20(3):177-85.

PMID:
16306998
10.

Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.

Anantharaman R, Bhansali A, Bhadada SK, Kohli HS, Dutta P, Walia R, Jayaprakash P, Upreti V.

Indian J Med Res. 2010 Jul;132:42-7.

11.

Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.

Mazerska M, Myśliwiec M.

Adv Med Sci. 2009;54(1):37-40. doi: 10.2478/v10039-009-0015-6.

PMID:
19505872
13.

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.

Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.

Hypertens Res. 2002 Nov;25(6):849-55.

14.

A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.

Anantharaman R, Bhansali A, Bhadada SK, Kohli HS, Walia R, Shanmugasundar G, Jayaprakash P.

Indian J Med Res. 2011 Nov;134(5):658-63. doi: 10.4103/0971-5916.90991.

15.

Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

Crepaldi G, Carraro A, Brocco E, Adezati L, Andreani D, Bompiani G, Brunetti P, Fedele D, Giorgino R, Giustina G, et al.

Acta Diabetol. 1995 Oct;32(3):203-8.

PMID:
8590792
16.

Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

Ekinci EI, Thomas G, Thomas D, Johnson C, Macisaac RJ, Houlihan CA, Finch S, Panagiotopoulos S, O'Callaghan C, Jerums G.

Diabetes Care. 2009 Aug;32(8):1398-403. doi: 10.2337/dc08-2297. Epub 2009 Jun 23.

20.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

PMID:
25399731
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk